Adjunct T2DM therapies include sodium-glucose transport protein 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/GIP agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, insulin secretagogues, and thiazolidinediones [17,19,20,25]. Here, DPP4 is linked to type 2 diabetes mellitus.